Oncology Xagena
Ibrutinib ( Imbruvica ), a once-daily Bruton’s tyrosine kinase ( BTK ) inhibitor approved for various B-cell malignancies, also inhibits other kinases, such as ITK and ETK ( Wang Clin Cancer Res 2018 ...
Preclinical evidence has suggested that Niraparib ( Zejula ), a poly (ADP-ribose) polymerase inhibitor, may synergise with PD-1 inhibitors. Pembrolizumab ( Keytruda ) is a PD-1 inhibitor approved a ...
MET exon 14 skipping mutations ( METex14 ) are seen in 3-4% of patients with non-small cell lung cancer ( METex14 NSCLC ) and are associated with poor outcomes. In the phase 2 GEOMETRY mono-1 stud ...
The phase III SPARTAN study evaluated Apalutamide ( Erleada ) vs Placebo in patients with non-metastatic castration-resistant prostate cancer ( nmCRPC ) who had prostate-specific antigen doubling time ...
There has been an only indirect comparison between Pembrolizumab ( Keytruda ) and Pembrolizumab plus chemotherapy in patients with non-small cell lung cancer ( NSCLC ) and high programmed death-ligand ...
Non-clear cell renal cell carcinoma ( nccRCC ) encompasses a heterogenous group of histologies comprising approximately 25% of all renal cell carcinoma ( RCC ) diagnoses with worse outcomes than clear ...
Castration-resistant prostate cancer ( CRPC ) is defined as disease progression during ADT ( androgen deprivation therapy ), with serum testosterone at castrate levels. The absence of metastases ( M0 ...
Data from the five-year analysis featuring extended follow-up from the phase III COMBI-AD study have confirmed that 12 months of adjuvant therapy with Dabrafenib ( Tafinlar ) plus Trametinib ( Mekinis ...
RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers ( NSCLCs ). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective RET inhibition are unknown. ...
Among patients with non–small-cell lung cancer ( NSCLC ), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib ( Tabrecta ), a selective inhibitor of t ...
A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer ( NSCLC ). Researchers have evalua ...
Sintilimab ( Tyvyt ), an anti-PD-1 antibody, in combination with Pemetrexed and Platinum has shown promising activity for non-squamous non-small cell lung cancer ( nsqNSCLC ) in a phase 1b study. T ...
Ensartinib is a novel second-generation ALK tyrosine kinase inhibitor ( TKI ). In phase 1/2 studies, Ensartinib showed promising activity in patients with ALK+ non-small cell lung cancer ( NSCLC ) who ...
Malignant pleural mesothelioma ( MPM ) is a highly aggressive cancer; most patients are diagnosed with unresectable disease, and the 5-year survival rate is less than 10%. Standard of care treatmen ...
Nivolumab ( Opdivo ) + Ipilimumab ( Yervoy ) was shown to improve overall survival ( OS ) and durability of response versus chemotherapy in first line ( 1L ) advanced non-small cell lung cancer ( NSCL ...
